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a  b  s  t  r  a  c  t
Immune reconstitution inﬂammation syndrome typically occurs within days after patients
undergo highly active anti-retroviral therapy and is a big hurdle for effective treatment of
AIDS patients. In this study, we monitored immune reconstitution inﬂammation syndrome
occurrence  in 238 AIDS patients treated with highly active anti-retroviral therapy. Among
them,  immune reconstitution inﬂammation syndrome occurred in 47 cases (19.7%). Immune
reconstitution  inﬂammation syndrome patients had signiﬁcantly higher rate of opportunis-
tic  infection (p < 0.001) and persistently lower CD4+ cell count (p < 0.001) compared to the
non-immune  reconstitution inﬂammation syndrome patients. In contrast, no signiﬁcant
differences  in HIV RNA loads were observed between the immune reconstitution inﬂam-
mation  syndrome group and non-immune reconstitution inﬂammation syndrome group.
These  data suggest that a history of opportunistic infection and CD4+ cell counts at baselinemay  function as risk factors for immune reconstitution inﬂammation syndrome occurrence
in  AIDS patients as well as potential prognostic markers. These ﬁndings will improve the
management  of AIDS with highly active anti-retroviral therapy.
and  partially understood condition. Publications on this sub-
ject  are mainly retrospective observational studies, and little
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Highly active anti-retroviral therapy (HAART) has been widely
used  to treat AIDS patients since 1995. HAART has been shown
to  strongly inhibit viral replication, reconstitute immune
function, control the incidence of opportunistic infections,
and  effectively reduce the morbidity and mortality of AIDS
1patients. However, about 10–30% of patients receiving HAART
show  clinical deterioration featuring increased chances of
opportunistic  infections and new pathogenic infections,
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Este é um artigo Open Access sob a licençadespite increased CD4+ counts and decreased plasma HIV viral
loads.2 This phenomenon was  described as immune reconsti-
tution  disease (IRD) or immune reconstitution inﬂammatory
syndrome (IRIS), which is life-threatening.3
Despite efforts to investigate clinical manifestations of
IRIS  and involved pathogens, IRIS remains a largely unknown
4is  known regarding prognostic factors and risk in differ-
ent  patient populations. In November 2009, Chinese Ministry
 de CC BY-NC-ND
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f Health announced that there were 320,000 HIV-infected
atients in China. Among them, more  than 80,000 patients
ave  received HAART as the ﬁrst-line treatment.5 However, the
revalence  of IRIS in Chinese AIDS patients receiving HAART,
he  potential factors which may  cause IRIS, and biological
arkers for predicting IRIS in AIDS have not yet been reported.
n  this study, we  analyzed several factors that may  predispose
atients receiving HAART to IRIS as well as clinical manifes-
ations  in 238 AIDS patients.
ubjects  and  method
ubjects
38 AIDS patients were  recruited for the study from October
007  to September 2009. AIDS was  diagnosed by HIV antibody
etection at the Center for Disease Control (Hunan Province,
hina).  Patients were  informed of the purpose of medication,
ossible side effects, and signed consent forms were evalu-
ted  and approved by Medical Ethics Committee in Second
iangya  Hospital (Hunan Province, China). All treatments used
n  this study complied with requirements of the National AIDS
ree  Antiviral Therapy Manuals in China (the second edition).
atients  were monitored for 24 weeks. Patient characteris-
ics  including gender, age, occupation, possible transmission
oute,  medical history, and the history of opportunistic infec-
ion  before HAART were recorded.
A prospective observational criterion was  followed so
hat  patients who developed IRIS were allocated to the IRIS
roup  (n = 47), while the rest was  assigned to non-IRIS groups
n  = 191). Blood samples were collected at baseline, 12th week
nd  24th week after the initiation of HAART and subjected to
 series of tests, such as HIV RNA viral load, CD4+ cell count,
iochemical tests, and pathogen detection. Clinical symptoms
ere  detected in a timely manner to guide diagnosis and treat-
ent  in practice. In addition, the same tests were performed
n  31 healthy volunteers (20 male and 11 female), with an
verage  age of 31.1 ± 5.4 years.3
nstruments  and  reagents
onoclonal antibodies including APC-CD4, PE-CD8, FITC-CD3,
erCP-CD45 and disposable hemolysin FACS lysing solu-
ion  were purchased from BD Biosciences (Shanghai, China).
uman  HIV-1 ﬂuorescence quantitative polymerase chain
eaction  diagnostic kits were purchased from Shenzhen PG
iotechnology Company (Shenzhen, China). MK  2 ELISA kits
ere  from Labsystems Dragon (Wellscan, Finland). FACS Cal-
bur  ﬂow cytometry was  purchased from BD Biosciences.
eneAmp PCR system 5700 was  purchased from Applied
iosystems (Carlsbad, CA, USA).
iagnostic  criteria  of  IRIShere are no universally accepted clinical diagnostic criteria
or  IRIS currently. However, a tentative deﬁnition and diagnos-
ic  criteria has been worked out in an international meeting
eld  in Uganda, December 2006, attended by over one hundred3;1  7(2):170–173  171
experts  in this ﬁeld. IRIS is deﬁned according to the Interna-
tional  Network for the Study of HIV-associated IRIS (INSHI).6
Statistical  analysis
Data were analyzed using SPSS (version 13.0) statistical
software package and presented as mean values ± standard
deviation (SD). The comparison of parametric data between
groups  was  performed using t test. Non-parametric data were
analyzed  using Wilcoxon Rank-sum test. p < 0.05 was consid-
ered  statistically signiﬁcant.
Results
History  of  opportunistic  infections  is  a  risk  factor  for  IRIS
during  HAART
Among 238 AIDS patients receiving HAART, 47 cases (19.7%)
developed  IRIS within 24 weeks after initial HAART adminis-
tration.  There were no signiﬁcant differences in gender, age,
route  of infection, duration of infection, or HAART regimens
between IRIS patients and non-IRIS patients. However,  more
patients  in the IRIS group had a history of opportunistic infec-
tions  before the initiation of HAART than in the non-IRIS group
(Table  1) (68.1% vs. 22.5%, p < 0.001). This suggested that a his-
tory  of opportunistic infections before HAART is a risk factor
for  IRIS occurrence during HAART.
Decrease  in  HIV  viral  load  in  patients  is  not  a  risk  factor
for  IRIS  during  HAART
HIV RNA viral load in IRIS group decreased robustly from 4.94
at  baseline to 2.82 at the 12th week. Then HIV  RNA level further
decreased  to 2.65 at the 24th week (Table 2). There was  no
signiﬁcant difference in the viral load between the two groups
at  all three time points. No virus rebound in either group was
detected  during the 24-week follow-up.
Increase  in  CD4+ T  cell  count  is  likely  risk  factor  for  IRIS
during  HAART
In the IRIS group, CD4+ cell count increased from 48/L at base-
line  to 118/L at the 12th week, and to 165/L at the 24th week,
respectively. Similarly, CD4+ cell count persistently increased
in  non-IRIS patients. At all three time points, the differences in
the absolute number of CD4+ cells between IRIS and non-IRIS
patients  are statistically signiﬁcant (Table 3). These data indi-
cate  that patients with low level of baseline CD4+ cell count
are  more  likely to develop IRIS.
Discussion
In this study, we identiﬁed that a history of opportunistic
infections and low CD4+ cell counts before patients receiving
HAART are risk factors for IRIS development. To the best of
our  knowledge, this is the ﬁrst prospective study to observe
IRIS  in real time after HAART therapy. Also, this is the ﬁrst
report  for the incidence of IRIS in China. Our results showed
that  19.7% of AIDS patients developed IRIS, which is consistent
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Table 1 – Clinicopathological characteristics in patients receiving HAART.
All patients (n = 238) IRIS group (n = 47) Non-IRIS group (n = 191) p-value
Sex
Male 163 (68.4%) 32 (68.1%) 131 (68.6%) 0.947
Age
Mean (range) 38.3 (30–45) 37.8 (30–44) 38.4 (29–47) 0.435
Routes of infection
Sex  contact 150 (63%) 30 (63.8%) 130 (68.1%) 0.580
Intravenous injection of drugs 69 (29%) 12 (25.5%) 47 (24.6%) 0.895
Blood transfusion 4 (1.7%) 0 (0.0%) 4 (2.1%) 0.317
Others 15 (6.3%) 5 (10.6%) 10 (5.2%) 0.172
Duration of HIV infection before HAART (year)
Mean (range) 3.2 (2.1–6.2) 3.1 (1.9–6.0) 3.2 (2.0–6.3) 0.931
Opportunistic infections before HAART
Mean  75 (31.5%) 32 (68.1%) 43 (22.5%) <0.001
HAART regimen
AZT  + 3TC + NVP 150 (63.0%)  29 (61.7%) 121 (63.4%) 0.834
d4T + 3TC + NVP 36 (15.1%) 5 (10.6%) 31 (16.2%) 0.338
AZT + 3TC + EFV 24 (10.1%) 4 (8.5%) 20 (10.5%) 0.689
d4T + 3TC + EFV 23 (9.7%) 8 (17.0%) 15 (7.9%) 0.057
Others 5 (2.1%) 1 (2.1%) 4 (2.1%) 0.989
HAART, highly active anti-retroviral therapy.
Table 2 – Decrease in HIV viral load over time following
HAART treatment.
Unit: Log10 (viral
copies/mL)
Non-IRIS
group (n = 50)
IRIS  group
(n = 47)
p-value
Baseline
HIV RNA 5.18 ± 0.59 4.94 ± 0.81 0.129
Number of samples
below  LOD
0 0
12th  week
HIV RNA 2.86 ± 0.39 2.82 ± 0.43a 0.764
Number of samples
below  LOD
22 (44.0%) 24 (52.2%)
24th  week
HIV RNA 2.63 ± 0.48 2.65 ± 0.54a 0.917
Number of samples
below  LOD
47 (94.0%) 44 (93.6%)
HAART, highly active anti-retroviral therapy; LOD, limit of detection.
aNo statistical signiﬁcance observed.
Table 3 – Increase in CD4+ T cells over time following
HAART  treatment.
Unit: number/L Non-IRIS group IRIS group p-value
Baseline n = 191 n = 47
CD4+ cell count 146 ± 90 48 ± 63 <0.001
12th week n = 186 n = 46
CD4+ cell count 174 ± 116 118 ± 62 0.019
24th week n = 175 n = 44
CD4+ cell count 269 ± 129 165 ± 116 <0.001
HAART, highly active anti-retroviral therapy; IRIS, immune recon-
stitution inﬂammation syndrome.with the 10–30% incidence rate reported by other groups.7
No signiﬁcant differences in age, gender, or route of trans-
mission were observed between IRIS patients and non-IRIS
patients (p > 0.05). No statistically signiﬁcant difference was
observed  between different drug regimens (p > 0.05, data not
shown).
At  present, there is no universal deﬁnition for IRIS. Clini-
cians  worldwide follow a set of loose guidelines to determine
whether or not a patient developed IRIS such as: appearance
of  atypical clinical manifestations, aggravation of conditions
after  HAART initiation, evidence of viral load reduction, as
well  as immunological recovery (exempliﬁed by the tuberculin
skin  test turning from negative to positive), clinical manifesta-
tions  deteriorated due to unknown inﬂuences other than drug
resistance  or side effects, etc.8 In our study, we  utilized INSHI
criteria  for early IRIS diagnosis, which is widely accepted by
researchers  and clinicians.9 Changes in HIV RNA viral load and
CD4+ T cell counts were  explicitly requested for the diagnosis
of  IRIS previously. However, these tests were  not done rou-
tinely  due to the lack of resources, particularly in developing
countries. In China, HIV RNA viral load test is only performed
every  6 or 12 months after the initiation of HAART, and CD4+ T
cells  are tested every three months. Therefore, it was  difﬁcult
to  monitor the occurrence of IRIS in a timely manner. In this
study,  we tried to deﬁne clinical symptoms that closely corre-
late  with IRIS to decrease the heavy dependence on laboratory
indices.3,10 Other reasons why compulsive testing of HIV RNA
viral  load and CD4+ T cell counts is not needed include: viral
load  decreased dramatically in most patients who  received
HAART  regardless of IRIS development11; in some cases, IRIS
occurred  before the rise of CD4+ T cell count.12 In addition,
+the number of CD4 T cells in peripheral blood may  not cor-
relate  with its function.13 Because of these ﬂaws, CD4+ T cell
count  has not been considered a necessary parameter for IRIS
diagnosis.13
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Our study identiﬁed two factors which signiﬁcantly cor-
elated  with IRIS occurrence. The ﬁrst is a history of
pportunistic infections before HAART.14,15 A majority of IRIS
atients  (68.1%) had opportunistic infections before HAART,
hich  is signiﬁcantly more  than non-IRIS patients (22.5%)
p  < 0.001). Therefore, a history of opportunistic infections may
e  a risk factor for IRIS. The second factor is CD4+ T cell
ount at baseline, but not after HAART. It has been shown that
atients  with more  than 350/L CD4+ T cells are unlikely to
evelop  IRIS. The risk for IRIS increases signiﬁcantly when
D4+ T cell counts drop below 100/L.16 Consistently, our
esults showed that 85.1% of IRIS patients had a CD4+ cell
ount  below 100/L before HAART, which was  2-fold higher
han  non-IRIS patients (p < 0.001). There may  be multiple rea-
ons  for this difference in CD4+ cell count: (1) patients with
ower  CD4+ T cell count are usually at more  advanced stages
f  the disease, and (2) low CD4+ T cell count suggests severe
amage to the immune system, and the inability to maintain
omeostasis.
Whether HIV RNA viral load is a risk factor for IRIS remains
ontroversial. Shelburne et al. showed that rapid reduction of
iral  load correlates with higher chance of developing IRIS.17 In
ontrast, Ratnam et al. study suggested that there is no statis-
ically  signiﬁcant difference in the decrement of HIV RNA viral
oad  between high risk and low risk groups.4 Our data agree
ith  the latter. Although viral load is an informative test, our
tudy  could not determine its predictive value.
IRIS is a life-threatening disease for AIDS patients. Mortal-
ty  rates for IRIS is less than 5% in Europe and North America,
nd  considerably higher in less resourceful districts.12 Life
pan  for IRIS patients vary greatly, depending on the type of
athology,  affected organs, etc.18 Close collaboration between
linicians and researchers in our study as well as prompt feed-
ack  from laboratory data assured that the best treatment was
iven  to the patients. Only two patients passed away (4.3%
ortality  rate) during our 6-month study. Clearly, close obser-
ation  will improve our understanding of IRIS.
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